What Characteristics at Baseline Are Associated with the Glucose-Lowering Effect of Colestimide in Patients with Type 2 Diabetes with Hypercholesterolemia?

被引：0
|
作者：
Suzuki, Tatsuya
Watanabe, Kentaro
Ouchi, Motoshi
Suzuki, Kazunari
Sekimizu, Kenichi
Nakano, Hiroshi
Oba, Kenzo
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2354-PO
引用
收藏
页码：A626 / A626
页数：1
相关论文
共 50 条
  • [1] What Characteristics at Baseline Are Associated with the Glucose-lowering Effect of Colestimide in Patients with Type 2 Diabetes and Hypercholesterolemia According to Response to Treatment?
    Suzuki, Tatsuya
    Tsunoda-Kubota, Misako
    Aoyama, Junya
    Futami-Suda, Shoko
    Hashimoto, Masao
    Igari, Yoshimasa
    Watanabe, Kentaro
    Kigawa, Yoshiaki
    Nakano, Hiroshi
    Oba, Kenzo
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2013, 80 (03) : 211 - 217
  • [2] Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia
    Yamakawa, Tadashi
    Kaneko, Takeshi
    Shigematu, Erina
    Kawaguchi, Junko
    Kadonosono, Kazuaki
    Morita, Satoshi
    Terauchi, Yasuo
    ENDOCRINE JOURNAL, 2011, 58 (03) : 185 - 191
  • [3] Mechanisms of glucose-lowering effect by rosiglitazone in patients with type 2 diabetes
    Miyazaki, Y
    Matsuda, M
    Mahankali, A
    Mahankali, S
    Cusi, K
    Mandarino, L
    Defronzo, R
    DIABETES, 2001, 50 : A126 - A127
  • [4] Personalized glucose-lowering effect of chiglitazar in type 2 diabetes
    Huang, Qi
    Zou, Xiantong
    Chen, Yingli
    Gao, Leili
    Cai, Xiaoling
    Zhou, Lingli
    Gao, Fei
    Zhou, Jian
    Jia, Weiping
    Ji, Linong
    ISCIENCE, 2023, 26 (11)
  • [5] Glucose-lowering effect of whey protein depends upon clinical characteristics of patients with type 2 diabetes
    Almario, Rogelio U.
    Buchan, Wendy M.
    Rocke, David M.
    Karakas, Sidika E.
    BMJ OPEN DIABETES RESEARCH & CARE, 2017, 5 (01)
  • [6] Glucose-lowering medicines for type 2 diabetes
    Davoren, Peter
    AUSTRALIAN FAMILY PHYSICIAN, 2015, 44 (05) : 272 - 276
  • [7] High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes
    Kun Yang
    Haining Wang
    Rui Wei
    Wenhua Xiao
    Qing Tian
    Chen Wang
    Jin Yang
    Tianpei Hong
    Acta Diabetologica, 2021, 58 : 595 - 602
  • [8] High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes
    Yang, Kun
    Wang, Haining
    Wei, Rui
    Xiao, Wenhua
    Tian, Qing
    Wang, Chen
    Yang, Jin
    Hong, Tianpei
    ACTA DIABETOLOGICA, 2021, 58 (05) : 595 - 602
  • [9] Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
    Prattichizzo, Francesco
    La Sala, Lucia
    Ryden, Lars
    Marx, Nikolaus
    Ferrini, Marc
    Valensi, Paul
    Ceriello, Antonio
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (2_SUPPL) : 73 - 80
  • [10] Glucose-lowering effects of sulfasalazine in type 2 diabetes
    Haas, RM
    Li, P
    Chu, JW
    DIABETES CARE, 2005, 28 (09) : 2238 - 2239
12345